Compare Novartis AG (NVS) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Ryanair Holdings plc — how do they compare? Novartis AG trades at $138.16 (market cap $262.64B), while Ryanair Holdings plc trades at $54.25 (market cap $27.58B). The key difference: Novartis AG is far larger — about 9.5× Ryanair Holdings plc's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | RYAAY | |
|---|---|---|
Market Cap | $262.64B | $27.58B |
Sector | Health | Industrials |
52-Week High | $168.62 | $73.82 |
52-Week Low | $121.80 | $53.24 |
Enterprise Value | $303.97B | $24.53B |
Dividend Yield | 3.44% | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
RYAAY trades at $54.37, down 1.79% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing strong revenue growth trends. Recent news highlights operational challenges including traffic outlook reductions and cost pressures from unhedged fuel. Cash flow remains positive from operations but net cash flow turned negative in 2025 and 2026 projections.
The outlook is cautious due to near-term headwinds from fuel costs and competitive pricing, but long-term fundamentals remain solid with attractive valuation multiples. Investment opportunity exists for value-oriented investors given low P/E of 13.09 and strong profitability metrics. Key risks include oil price volatility and winter capacity constraints affecting profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
